I thought my fellow rectal cancer NED peeps might be interested in this trial.
My oncologist is the primary investigator in this study and informed me yesterday that the study, S0820, Adenoma and Second Primary Prevention Trial (PACES) is now being opened up to include rectal cancer survivors.
The purpose of the trial is The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon cancer.
You can find out more about the trial at
http://www.clinicaltrials.gov & just search PACES.